1.Clinical features and treatment of 160 cases of liver cirrhosis with portal vein thrombosis
Yuanyuan GOU ; Song HE ; Kailing WU ; Qiuxia SONG
Chinese Journal of Digestion 2018;38(7):455-460
Objective To analyze the clinical characteristics of patients with liver cirrhosis complicated with portal vein thrombosis (PVT) and to explore the high risk factors of PVT formation for the prevention and early treatment of PVT.Methods From January 2012 to August 2017,at the Second Hospital Affiliated to Chongqing Medical University,160 hospitalized liver cirrhosis patients complicated with PVT were selected as PVT group and secondary PVT caused by other factors were excluded.At the same time,250 patients with liver cirrhosis without PVT were enrolled as the control group.According to the history of splenectomy,the patients were divided into splenectomy group and non-splenectomy group.The risk factors correlated with the formation of PVT such as hemoglobin,platelet count,prothrombin time (PT),international normalized ratio (INR) and prothrombin activity were collected.T test,chisquare test and non-parameter rank test were performed for the comparison of above indexes between PVT group and control group.Single factor analysis and multifactor logistic regression were used to analyze the risk factors of PVT formation.Results The average age of patients in PVT group ((54.5 ±11.4) years) was significantly older than that in control group ((51.8±911.9) years,t=2.29,P=0.02).The results of multifactor logistic regression analysis showed that hemoglobin,platelet count,PT and INR were risk factors of PVT formation (all P<0.05).The proportion of patients with Child-Pugh class C cirrhosis in PVTgroup was higher than that in control group (16.2%,26/160 vs.4.4%,11/250),and the difference was statistically significant (x2 =16.60,P<0.01).In PVT group,27.5% (44/160) patients had a history of splenectomy,and 8.4% (21/250) patients of the control group had a history of splenectomy,and the difference between two groups was statistically significant (x2=26.70,P<0.01).The platelet counts of patients with splenectomy were higher than those of patients without splenectomy ((176.2±98.7)× 109/L vs.(78.3±57.8) × 109/L),and the difference was statistically significant (t=11.08,P<0.01).The incidence of complications in PVT group was much higher than that in control group (45.0%,72/160 vs.10.0%,25/250,x2=66.17,P<0.05).There were no statistically significant differences in the incidence of gastrointestinal bleeding and mortality between PVT treatment group and non-treatment group (25.6%,11/43 vs.23.8%,10/42;18.6%,8/43 vs.31.0%,13/42,respectively;both P>0.05).Conclusions Decreased hemoglobin,increased platelet count,prolonged PT,increased INR and Child-Pugh classification are the risk factors for PVT formation.Increased platelet after splenectomy is an independent risk factor for PVT formation.
2.Clinical Experience of You Zhaoling in Treating Polycystic Ovarian Syndrome
Guiyun WANG ; Huiping LIU ; Lingyu WU ; Xiaolan WU ; Kailing WANG ; Zhaoling YOU
Chinese Journal of Information on Traditional Chinese Medicine 2024;31(10):181-185
This article summarized Professor You Zhaoling's clinical experience in the treatment of polycystic ovary syndrome(PCOS).It is believed that kidney deficiency and blood stasis are the basic etiology and pathogenesis,with liver and spleen disorders.Clinical treatment is based on tonifying the kidney and replenishing essence,promoting blood circulation and resolving stasis,supplemented by soothing the liver,strengthening the spleen,and resolving dampness;treatment should also be based on the patients'stage of illness,age,and body type;basic body temperature and B-ultrasound should be skillfully uses to monitor ovulation,and four methods of regulating bubbles were creatively created;an original hypothetical menstrual stimulation method for PCOS patients with menstrual disorders was created.Professor You's clinical experience has demonstrated the characteristics of TCM treatment,providing a new approach for the TCM treatment of PCOS.
3.The role of combined analysis of E2F3a and CASP8AP2 expression in prognosis evaluation in pediatric acute lymphoblastic leukemia
Fenfen JIN ; Yanyan MEI ; Kailing WANG ; Chanjuan WANG ; Minyuan WU ; Lei CUI ; Zhigang LI
Chinese Journal of Applied Clinical Pediatrics 2018;33(9):697-701
Objective To investigate the role of combined analysis of E2F3a and CASP8AP2 expression in prognosis evaluation in pediatric acute lymphoblastic leukemia (ALL). Methods The study included 141 newly diag-nosed pediatric ALL patients enrolled at the Hematology Center,Beijing Children′s Hospital,Capital Medical Universi-ty between March 2008 and July 2010,including 97 boys and 44 girls(aged 1. 2 - 15. 5 years,median 5. 2 years). E2F3a and CASP8AP2 expressions were quantified in 141 children with ALL by adopting real - time quantitative poly-merase chain reaction (qPCR). Receiver operating characteristic (ROC)curve was used to find the best cut - off point to divide the patients into E2F3a or CASP8AP2 low - and high - expression groups,and the treatment outcome between the groups was compared. Cox regression was used to analyze the prognostic significance of the combined expression of E2F3a and CASP8AP2. Results The estimated 5 - year relapse free survival(RFS)rate,event free survival(EFS) rate and overall survival (OS)rate of patients with low - E2F3a and low - CASP8AP2 expression were (58. 9 ± 10. 0)%,(56. 0 ± 9. 9)% and (72. 0 ± 9. 0)%,respectively. They were significantly lower than those of patients with high - E2F3a and high - CASP8AP2 expression,whose RFS,EFS and OS were (94. 9 ± 2. 5)%,(93. 7 ± 2. 7)% and (96. 2 ± 2. 2)%,and the differences were all statistically significant(all P < 0. 05),respectively. Compared with other patients,the one with low expression of both E2F3a and CASP8AP2 had a poorer prognosis. In addition to MLL rear-rangements and minimal residual disease level at the end of remission induction,low expression of both E2F3a and CASP8AP2 remained as independent prognostic factors. Conclusion Low expressions of E2F3a and CASP8AP2 pre-dict poor prognosis in pediatric ALL. Combined assessment of E2F3a and CASP8AP2 expression could predict poor prognosis and relapse more accurately.
4.Experience of Using Charcoal-Processed Traditional Chinese Medicine in the Treatment of Gynecological Hemorrhagic Disorders
Xiaolan WU ; Zhaoling YOU ; Guiyun WANG ; Kailing WANG ; Xiaojuan YE ; Lingyu LIAO ; Yueheng LI ; Huiping LIU
Journal of Traditional Chinese Medicine 2025;66(3):308-311
Charcoal-processed traditional Chinese herbal medicine has various therapeutic effects, including astringing, hemostasis, anti-diarrhea, clearing heat, tonifying, and warming the interior. This paper summarizes the clinical application features, compatible experiences, dosages, and precautions for over 20 types of charcoal-processed herbal medicine in the treatment of gynecological bleeding disorders caused by dysfunctions such as dysfunctional uterine bleeding, endometriosis, uterine incision pseudocavity, and vaginal bleeding resulting from threatened miscarriage. The charcoal-processed herbal medicine include Huangqin (Scutellaria Baicalensis) Charcoal, Dahuang (Rheum Palmatum) Charcoal, Cebai (Platycladus Orientalis) Charcoal, Diyu (Sanguisorba Officinalis) Charcoal, Daji (Cirsium Setosum) Charcoal, Xiaoji (Cirsium Japonicum) Charcoal, Shengdi (Rehmannia Glutinosa) Charcoal, Aiye (Artemisia Argyi) Charcoal, Paojiang (Zingiber Officinale) Charcoal, Xuduan (Dipsacus Asper) Charcoal, Duzhong (Eucommia Ulmoides) Charcoal, Qiancao (Rubia Cordifolia) Charcoal, Puhuang (Typha Angustifolia) Charcoal, Shanzha (Crataegus Pinnatifida) Charcoal, Jingjie (Schizonepeta Tenuifolia) Charcoal, Xueyu (Carthamus Tinctorius) Charcoal, Zonglyu (Areca Catechu) Charcoal, Wumei (Prunus Mume) Charcoal, Shudahuang (Rheum Officinale) Charcoal, Lianfang (Nymphaea Alba) Charcoal, Mianmaguanzhong (Clematis Armandii) Charcoal, and Oujie (Nelumbo Nucifera) Charcoal.